ALTA LIFE SCIENCES

[FirstWord HealthTech @fwhealthtech]

DeepUll seeks to replace 40-year-old sepsis Dx approach https://t.co/ymhhrCucOz #sepsis #DeepUll #moleculardiagnostics #healthtech #advancedIVD #AI #innovation

[Expansión Start Up @exp_startup]

Los fondos obtenidos por la 'start up' fundada en 2020 por Jordi Carrera y Rafel Bru se utilizarán para avanzar en el desarrollo de su plataforma de reconocimiento de la sepsis. @tinofernandez @exp_startup https://t.co/qbh461Y1F3

[Expansión Catalunya @exp_catalunya]

DeepUll consigue 13 millones para avanzar en el diagnóstico de la sepsis https://t.co/BDJHsZx267

[Parc Científic de Barcelona @PCB_UB]

#PCBCommunity | #DeepUll, based in #PCB_UB, raises €13M Series B financing to progress its first-in-class early #sepsis recognition platform towards the market

@CDTI_innovacion @CienciaGob @ICOgob @_AltaLS @KurmaPartners @ui_invest #MedicalDiagnostics
https://t.co/0eLdgMjAeE

[binx health @binxhealth]

binx health announced today the appointment of Todd Bennett as CCO. Todd is an accomplished industry veteran, having held multiple executive leadership roles at several high-growth diagnostic and healthcare technology companies. Read more here: https://t.co/7IK29RNVWn

[binx health @binxhealth]

binx health brings convenient access to high-quality reference laboratory-based testing with the potential to drive better outcomes. Learn more about how we can service your organization or community: https://t.co/bL5TShFUNE #COVID19 #STItesting

[Accure Therapeutics @AccureTherapeut]

We are pleased to announce that we have signed an exclusive worldwide licensing agreement with Oculis to develop and commercialize a potentially disease modifying therapy to protect and prevent damage to the optic nerve and retina. #glaucoma #opticneuritis
https://t.co/9X9QoOOsKf

[ALTA LIFE SCIENCES @_AltaLS]

Happy to announce that Oculis Strengthens Leading Ophthalmology Pipeline by InLicensing Neuroprotective Drug Candidate for Glaucoma from @AccureTherapeut

https://t.co/bHoDB0qElB

[PEPTOMYC @peptomyc]

MYC inhibition halts metastatic breast cancer progression by blocking tumor growth, invasion & seeding. Congratulations @peptomyc Team and @VHIO! @LauraSoucek & Daniel Massó-Vallés!

[Cancer Research Communications @CRC_AACR]

#JustPublished! MYC inhibition is anti-metastatic in #BreastCancer by Massó-Vallés, @LauraSoucek et al.
https://t.co/A535VXljex
@peptomyc @VHIO #openaccess

[RTVE Noticias @rtvenoticias]

"Parar la proteína 'myc' significa parar el crecimiento de tumores humanos"

En el #Canal24Horas han hablado con Laura Soucek, jefa del grupo del Instituto de Oncología Vall d'Hebron (@VHIO)

https://t.co/kFDiAdSejV

[PEPTOMYC @peptomyc]

"𝑈𝑛 𝑓𝑎̀𝑟𝑚𝑎𝑐 𝑟𝑒𝑣𝑜𝑙𝑢𝑐𝑖𝑜𝑛𝑎𝑟𝑖 𝑞𝑢𝑒 𝑒𝑙𝑖𝑚𝑖𝑛𝑎 𝑐𝑒̀𝑙·𝑙𝑢𝑙𝑒𝑠 𝑐𝑎𝑛𝑐𝑒𝑟𝑜𝑠𝑒𝑠"
@LauraSoucek, CEO de @peptomyc, fue entrevistada ayer en el programa REVOLUCIÓ 4.0 de @CatalunyaRadio
https://t.co/dnArNnwpW0

[PEPTOMYC @peptomyc]

Peptomyc is hiring! We are looking for a Clinical distribution and Logistics manager.
More info here: https://t.co/V8l74OWmWS
If you are interested in this offer please send your CV to [email protected]

[PEPTOMYC @peptomyc]

Con motivo del día ᴅɪ́ᴀ Iɴᴛᴇʀɴᴀᴄɪᴏ́ɴᴀʟ ᴅᴇ ʟᴀ Eᴅᴜᴄᴀᴄɪᴏ́ɴ, @BusinessInsider entrevista a 61 empresarios, inversores, directivos e investigadores; comentan qué echaron en falta y qué cambiarían de su época en las aulas.
https://t.co/Qxv101afhS @LauraSoucek

[PEPTOMYC @peptomyc]

Rumbo a la Fase II @peptomyc https://t.co/TjkZsB5gli

[Webcapitalriesgo.com @WCapitalRiesgo]

#VentureCapital: @peptomyc logra 8,6 millones de sus socios y busca más inversores https://t.co/KFXDhYw5k0 a través de @expansioncom

[Ona Therapeutics @OnaTherapeutics]

Very happy to welcome Dr Michel Detheux as Independent Chair to ONA’s board of directors. https://t.co/6nKSqtjHE3

[Valerie Vanhooren @valerievh001]

I am thrilled to welcome Dr Michel Detheux as Independent Chair of ONA’s board of directors.

[Ion Arocena @ionaro]

Enhorabuena a @SanifitLabs por este broche de oro a estos 17 años de compromiso y esfuerzo. Mérito de @perellojoan y todo el equipo, gracias a la apuesta de @CaixaCR @YsiosCapital @_AltaLS @InvivoCapital e #innvierte de @CDTIoficial
https://t.co/dw7GuKCvv5

[Webcapitalriesgo.com @WCapitalRiesgo]

#VentureCapital: @ViforPharmaES adquirirá @SanifitLabs, participada por @YsiosCapital, @CaixaCR, @_AltaLS, ColumbusVP, Healthequity y el @CDTIoficial https://t.co/KKZFpLAw4P